GlassScriptPhysician profile
Gerhardt S Wagner
NPI 1477716199
$5,297.34
in general payments reported to CMS, 2019-2025
19 companies · $932 in 2025
The $932 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $110 · 2021: $427 · 2022: $1,216 · 2023: $1,160 · 2024: $1,158 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.18 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.54 | 2021-2025 | Vraylar |
| Lundbeck LLC | $833.64 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $671.34 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $663.52 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $470.53 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $431.76 | 2021-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $262.90 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $217.99 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $195.26 | 2019-2020 | |
| Alkermes, INC. | $148.27 | 2021-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $133.69 | 2019-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $108.89 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $73.47 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $65.59 | 2023-2024 | Qelbree, Qelbree |
| Corium, LLC | $24.41 | 2023 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $23.36 | 2022 | |
| Avanir Pharmaceuticals, INC. | $20.36 | 2021 | |
| Noven Therapeutics, LLC | $12.08 | 2020 | |
| Almatica Pharma LLC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerhardt Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.